nach oben

International Journal of Clinical Oncology

Erschienen in:

22.10.2016 | Original Article

Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients

verfasst von: Lisette Del Corso, Lucia Biale, Emanuele Luigi Parodi, Rodolfo Russo, Rosa Filiberti, Eleonora Arboscello

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Deferasirox (DFX) is used to reduce iron levels in patients with myelodysplastic syndrome (MDS) who develop iron overload after chronic red blood cell infusions. However, DFX can be associated with renal and gastrointestinal toxicities, which may cause treatment interruption or discontinuation. This study aimed to determine the effectiveness and safety of DFX in patients with MDS.

Methods

This multicenter, retrospective, observational study was conducted at two hospitals in Italy. Elderly patients with transfusion-dependent MDS received DFX for up to 12 months and were divided into two groups: group A comprised patients who were not under multidisciplinary assessment; group B comprised patients under multidisciplinary control. Treatment effectiveness was estimated by monitoring the serum ferritin (SF) levels throughout the study. Any treatment-related adverse events (AEs), clinically relevant analytical alterations, and reasons for treatment discontinuation were monitored.

Results

The study included 44 patients (13 female, 31 male; median age 77.0 years). At 3 months, SF levels decreased by ≥20 % in 29 and 31 % of patients in groups A and B, respectively, in 17 and 36 % of patients at 6 months, and in 22 and 58 % at 12 months. The most common AEs were diarrhea and increased serum creatinine, which were more frequent in group A. The discontinuation rate after renal AE was 15 and 5 % in groups A and B, respectively.

Conclusion

Multidisciplinary evaluation can be an effective strategy for monitoring renal function in patients on DFX therapy, to improve treatment adherence and overall efficacy in elderly patients with MDS.

Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361(19):1872–1885. doi:10.1056/NEJMra0902908 CrossRefPubMed

Aul C, Giagounidis A, Germing U (2001) Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 73(4):405–410CrossRefPubMed

Cogle CR (2015) Incidence and Burden of the Myelodysplastic Syndromes. Current hematologic malignancy reports 10(3):272–281. doi:10.1007/s11899-015-0269-y CrossRefPubMedPubMedCentral

Ma X, Does M, Raza A et al (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109(8):1536–1542. doi:10.1002/cncr.22570 CrossRefPubMed

Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088PubMed

Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465. doi:10.1182/blood-2012-03-420489 CrossRefPubMedPubMedCentral

Malcovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25(23):3503–3510. doi:10.1200/jco.2006.08.5696 CrossRefPubMed

Greenberg PL, Attar E, Bennett JM et al (2013) Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw 11(7):838–874PubMedPubMedCentral

Malcovati L, Hellstrom-Lindberg E, Bowen D et al (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122(17):2943–2964. doi:10.1182/blood-2013-03-492884 CrossRefPubMedPubMedCentral

10.

Ades L, Santini V (2013) Hypomethylating agents and chemotherapy in MDS. Best Pract Res Clin Haematol 26(4):411–419. doi:10.1016/j.beha.2013.09.010 CrossRefPubMed

11.

Brierley CK, Steensma DP (2016) Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter? Curr Opin Hematol 23(2):167–174. doi:10.1097/moh.0000000000000217 CrossRefPubMed

12.

NCCN (2013) Clinical Practice guidelines in oncology: myelodysplastic syndromes. version. 1

13.

NCCN (2014) Clinical Practice guidelines in oncology: myelodysplastic syndromes. version. 2

14.

Santini V, Alessandrino PE, Angelucci E et al (2010) Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 34(12):1576–1588. doi:10.1016/j.leukres.2010.01.018 CrossRefPubMed

15.

Cazzola M, Della Porta MG, Malcovati L (2008) Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program, pp 166–175. doi:10.1182/asheducation-2008.1.166

16.

Gattermann N (2012) Pathophysiological and clinical aspects of iron chelation therapy in MDS. Curr Pharm Des 18(22):3222–3234CrossRefPubMed

17.

Leitch HA, Vickars LM (2009) Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? Hematol Am Soc Hematol Educ Program, pp 664–672. doi:10.1182/asheducation-2009.1.664

18.

Kautz L, Jung G, Valore EV et al (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46(7):678–684. doi:10.1038/ng.2996 CrossRefPubMedPubMedCentral

19.

Leitch HA, Chan C, Leger CS et al (2012) Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res 36(11):1380–1386. doi:10.1016/j.leukres.2012.08.001 CrossRefPubMed

20.

Leitch HA, Leger CS, Goodman TA et al (2008) Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2(3):205–211CrossRef

21.

Rose C, Brechignac S, Vassilief D et al (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 34(7):864–870. doi:10.1016/j.leukres.2009.12.004 CrossRefPubMed

22.

Yang LP, Keam SJ, Keating GM (2007) Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs 67(15):2211–2230CrossRefPubMed

23.

Tokuhira M, Sagawa M, Watanabe R et al (2011) Management of oral iron chelator deferasirox for transfusion-dependent patients with hematological disorders: 2-year experience at a single institution in Japan. Int J Clin Med 2(03):224CrossRef

24.

Meerpohl JJ, Schell LK, Rucker G et al (2014) Deferasirox for managing iron overload in people with myelodysplastic syndrome. Cochrane Database Syst Rev 10:CD007461. doi:10.1002/14651858.CD007461.pub3

25.

Huang WF, Chou HC, Tsai YW et al (2014) Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events. Pharmacoepidemiol Drug Saf 23(11):1176–1182. doi:10.1002/pds.3657 CrossRefPubMed

26.

Wang R, Gross CP, Halene S et al (2009) Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 33(12):1594–1598. doi:10.1016/j.leukres.2009.02.005 CrossRefPubMedPubMedCentral

27.

Breccia M, Federico V, Latagliata R et al (2011) Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res 35(2):159–162. doi:10.1016/j.leukres.2010.06.005 CrossRefPubMed

28.

Della Porta MG, Malcovati L, Strupp C et al (2011) Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 96(3):441–449. doi:10.3324/haematol.2010.033506 CrossRefPubMed

29.

Sperr WR, Kundi M, Wimazal F et al (2013) Proposed score for survival of patients with myelodysplastic syndromes. Eur J Clin Invest 43(11):1120–1128. doi:10.1111/eci.12149 PubMed

30.

Diaz-Garcia JD, Gallegos-Villalobos A, Gonzalez-Espinoza L et al (2014) Deferasirox nephrotoxicity-the knowns and unknowns. Nat Rev Nephrol 10(10):574–586. doi:10.1038/nrneph.2014.121 CrossRefPubMed

31.

Brosnahan G, Gokden N, Swaminathan S (2008) Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant 23(10):3356–3358. doi:10.1093/ndt/gfn423 CrossRefPubMed

32.

Yew CT, Talaulikar GS, Falk MC et al (2010) Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis. Nephrology (Carlton) 15(3):377. doi:10.1111/j.1440-1797.2009.01183.x CrossRef

33.

European Medicines Agency (2013) Assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000670/WC500146154.pdf

34.

Food and Drug Administration (2007) New molecular entity (NME)—early safety findings. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm118813.htm

35.

Gattermann N, Finelli C, Porta MD et al (2010) Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 34(9):1143–1150. doi:10.1016/j.leukres.2010.03.009 CrossRefPubMed

36.

Porter J, Galanello R, Saglio G et al (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80(2):168–176. doi:10.1111/j.1600-0609.2007.00985.x PubMedPubMedCentral

37.

Ponticelli C, Musallam KM, Cianciulli P et al (2010) Renal complications in transfusion-dependent beta thalassaemia. Blood Rev 24(6):239–244. doi:10.1016/j.blre.2010.08.004 CrossRefPubMed

38.

Vichinsky E (2008) Clinical application of deferasirox: practical patient management. Am J Hematol 83(5):398–402. doi:10.1002/ajh.21119 CrossRefPubMed

Titel: Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients
verfasst von: Lisette Del Corso
Lucia Biale
Emanuele Luigi Parodi
Rodolfo Russo
Rosa Filiberti
Eleonora Arboscello
Publikationsdatum: 22.10.2016
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1042-5

A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer

Original Article

A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer

Original Article

Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer

Original Article

The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis

Review Article

Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study

Original Article

Status of oncologic specialties: global survey of physicians treating cancer

Original Article

Neu im Fachgebiet Onkologie

Studie zur HIFU bei Prostatakrebs lässt viele Fragen offen

22.01.2025
Prostatakarzinom
Nachrichten

Führt eine HIFU-Ablation beim Prostatakarzinom im Vergleich mit einer radikalen Prostatektomie zu ähnlichen onkologischen, aber besseren funktionalen Ergebnissen? Interimsdaten der französischen HIFI-Studie sind uneindeutig. In einem Kommentar zur Studie werden zumindest drei allgemeine Erkenntnisse herausgearbeitet.

Adipositas als negativer Prognosefaktor bei Kindern mit Krebs

Eine kanadische Studie weist darauf hin, dass Übergewicht zum Zeitpunkt der Krebsdiagnose ein unabhängiger Risikofaktor für schlechtere Überlebenschancen bei erkrankten Kindern und Jugendlichen sein könnte. Allerdings sind nicht alle Patientinnen und Patienten gleichermaßen betroffen.

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

20.01.2025
Risikofaktoren für Krebserkrankungen
Nachrichten

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients